新闻周刊:高价药正在让更多人面临死亡(2)（在线收听）

"I think it's important here that we notice that we the public, we the people, developed this drug. We paid for this drug, we led and developed all the patents to create PrEP [the commonly known name for Truvada] and then that patent has been privatized, despite the fact that the patent is owned by the public, who refused to enforce it," the representative said.

“我认为重要的是，我们要注意到，我们公众，我们人民，开发了这种药物。我们为这种药物支付了费用，我们领导并开发了所有的专利，创建了PrEP(特鲁瓦达的俗称)，然后该专利就被私有化了，尽管该专利属于拒绝执行该专利的公众。”

"There's no reason this should be $2,000 a month. People are dying because of it," she added.

“没有理由每月支付2000美元。人们因此而死亡，”她补充道。

As Ocasio-Cortez explained, the research that showed Truvada was effective at preventing HIV in humans, despite a user's potentially risky sexual activity, was almost entirely funded by U.S. taxpayers, according to The Washington Post. The U.S. government patented the treatment back in 2015, but it currently does not receive any profit from the drug. Instead, Gilead, which originally developed the drug for other treatments, has argued that the patent is not valid and continues to rake in billions annually.

据《华盛顿邮报》报道，正如奥卡西奥-科尔特斯所解释的那样，这项研究表明特鲁瓦达在预防人类感染艾滋病毒方面是有效的，尽管使用者有潜在的危险性行为，而且几乎完全是由美国纳税人资助的。美国政府早在2015年就为这种疗法申请了专利，但目前还没有从这种药物中获得任何利润。相反，最初为其他治疗方法开发这种药物的吉利德辩称，该专利无效，并继续以每年数十亿美元的速度暴利。

In fact, since Truvada was approved as an effective HIV treatment, Gilead has steadily increased its price. A 2018 report by NPR explained that the drug's wholesale price had increased 45 percent over the past six years. Although most health insurance in the U.S. covers Truvada, that does not benefit the millions of Americans who are not insured.

事实上，自从特鲁瓦达被批准为一种有效的艾滋病毒治疗，吉利德已经稳步提高了它的价格。美国国家公共电台2018年的一份报告解释说，这种药物的批发价格在过去六年中上涨了45%。尽管美国的大多数医疗保险都包括特鲁瓦达医保，但这并没有惠及数百万没有医保的美国人。

"With the amount of effort and time and taxpayer money that went into it, for CDC (the Centers for Disease Control and Prevention) and Gilead not to come to an agreement, so the taxpayer could get some of that money, is really unconscionable,'' Thomas Folks, who first researched Truvada's ability to prevent HIV in monkeys, told the Post earlier this year.

“花了这么多精力、时间和纳税人的钱，美国疾病控制和预防中心和吉利德没有达成协议，所以纳税人可以得到一部分钱，这实在是太不合理了。” 托马斯·福克斯是第一个研究特鲁瓦达在猴子身上预防艾滋病的能力的人，他在今年早些时候告诉《华盛顿邮报》。